Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs American Superconductor Corporation (AMSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs American Superconductor Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while American Superconductor Corporation trades at $32.44 (market cap $1.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19× American Superconductor Corporation's market cap, and American Superconductor Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMSC | |
|---|---|---|
Market Cap | $29.60B | $1.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $66.68 |
52-Week Low | $205.48 | $25.95 |
Enterprise Value | $27.56B | $1.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AMSC trades at $32.64, up 5.32% in 24 hours, with a bearish technical signal from moving averages. Recent Q1 2026 earnings missed estimates despite record revenue growth, while Q4 2025 and Q1 2026 beat expectations. The company shows strong profitability with a net income margin of 42.56% and ROE of 30.16%, but faces margin pressure and a high EV/EBITDA of 65.73. News highlights record orders and backlog growth amid concerns over valuation and business mix.
Outlook is mixed: bullish fundamentals from earnings beats and order momentum contrast with bearish technicals and valuation risks. Opportunities lie in Grid and Wind segment expansion, but investors face headwinds from margin compression and competitive pressures. Analyst consensus leans buy (53.33%), suggesting cautious optimism for growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →
